Fusobacterium Species Test · Stool

Most of the bacteria in your gut are helpful or neutral. Fusobacterium is one of the few groups that researchers have repeatedly caught showing up where it should not be: inside colorectal tumors, in inflamed bowel tissue, and in the stools of people years before a cancer diagnosis.

Measuring how much Fusobacterium is in your stool offers an early window into a specific pattern of gut disruption that standard bowel tests do not see. It is not a cancer diagnosis in a tube, but it is one of the clearest microbial signals that something in your gut environment may be tilting toward chronic inflammation.

What Fusobacterium Is and Where It Lives

Fusobacterium are bacteria that live without oxygen. They normally reside in the mouth, the gut, and other mucosal surfaces. The species that gets the most attention is Fn (Fusobacterium nucleatum), a bacterium that is common in dental plaque and can reach the gut through swallowing or the bloodstream.

Having some Fusobacterium in stool is normal. The concern is relative overgrowth, especially when Fn expands into gut tissue where it rarely lives in healthy people. Different subspecies, such as animalis and polymorphum, have different habits and different links to disease, which is one reason a single stool reading should be interpreted as a signal rather than a verdict.

Colorectal Cancer Risk

The strongest clinical story for Fusobacterium is in colorectal cancer (cancer of the colon and rectum). Fn DNA is enriched in tumor tissue and in the stools of people who have colorectal cancer. A meta-analysis of fecal Fusobacterium for detecting colorectal cancer reports a sensitivity of about 0.81 and specificity of about 0.77, meaning it correctly flagged roughly 81 out of 100 cancers and correctly cleared roughly 77 out of 100 healthy people.

Inside tumors, more Fusobacterium tends to mean a worse course. A study of more than a thousand colorectal cancer cases found that tumors carrying Fusobacterium DNA were associated with shorter survival. Other analyses link high tumor Fusobacterium to advanced stage, lymph node spread, and specific molecular subtypes. This does not prove the bacterium caused the cancer, but it consistently marks a more aggressive environment.

Fusobacterium in stool also adds information on top of the fecal immunochemical test (FIT), the standard non-invasive colorectal cancer screen. In one study, adding Fusobacterium quantification to FIT raised combined sensitivity for colorectal cancer to around 92%, catching many cancers that FIT alone missed, while preserving specificity above 90%.

One nuance matters. A large screening-colonoscopy study found that fecal Fusobacterium was strongly linked to established cancer but not to early adenomas (precancerous polyps). That suggests Fusobacterium may often be a passenger that thrives once a tumor forms, rather than a trigger for early lesions. Either way, a clearly elevated reading is a signal to take bowel health seriously.

Inflammatory Bowel Disease and Gut Dysbiosis

Fusobacterium shows up more often, and in more invasive forms, in the guts of people with inflammatory bowel disease (IBD), an umbrella term for Crohn's disease and ulcerative colitis. In a study of patients undergoing bowel biopsy, Fn strains isolated from inflamed tissue were more capable of invading the cells lining the gut than strains from healthy tissue. Higher Fn burden has also been flagged as a marker of early gut dysbiosis, the term researchers use when the balance of gut microbes shifts toward a less stable, more inflammatory state.

Oral Fn may also worsen ulcerative colitis through what researchers call the oral-gut axis, the idea that bacteria swallowed from the mouth can colonize the lower gut when conditions are favorable. This is one reason gum disease and bowel disease often travel together.

Links Beyond the Colon

Fusobacterium has been linked in human studies to several other conditions, though the evidence is less mature than for colorectal cancer. It is enriched in oral squamous cell carcinoma (a common form of mouth cancer) and in gastric cancer tissue, and salivary Fn outperformed traditional blood tumor markers for detecting gastric cancer in one Chinese study (AUC 0.813, meaning the test distinguished cases from controls about 81 times out of 100).

A review of epidemiologic evidence also connects Fn to cardiovascular disease, adverse pregnancy outcomes, rheumatoid arthritis, Alzheimer's, and respiratory infections. These are associations, not proof of cause. The common thread is that when Fusobacterium translocates from the mouth or gut and persists where it does not belong, it tends to keep the immune system on a low, chronic simmer.

A Note on Counterintuitive Findings

Most of what you will read presents Fusobacterium as a marker of gut trouble. But one prospective primary-care study followed people for ten years and found that detecting Fn DNA in stool did not predict which benign lesions would progress to cancer. And in oral squamous cell carcinoma, one cohort study reported that higher intratumoral Fn was associated with a more favorable prognosis in older, non-drinking patients. The takeaway is that Fusobacterium is best read as a pattern indicator, not a score where lower is always better. High levels in the presence of inflammation or a known lesion deserve attention. A single elevated reading in isolation is a prompt to look deeper, not to panic.

Reference Ranges

This is a research and early-clinical marker, not a test with universally agreed thresholds. Different labs use different methods (quantitative PCR, 16S rRNA sequencing, metagenomic shotgun sequencing) and report results in different units, from relative abundance percentages to DNA copy counts. Published studies in colorectal cancer typically compare the top third of Fusobacterium readings to the bottom two thirds rather than applying a universal cutpoint.

Because there is no standardized clinical cutpoint for stool Fusobacterium in healthy adults, the most useful interpretation is how your number compares to the lab's own reference distribution and, more importantly, how it moves on repeat testing in the same lab.

Compare your results within the same lab over time for the most meaningful trend. A shift across repeat tests is more informative than any single threshold.

When Results Can Be Misleading

A stool reading captures a snapshot of a living, shifting ecosystem. A few factors can distort what you see without meaning much about your underlying bowel health.

• Recent antibiotics: antibiotic courses reshape the gut microbiome for months and can artificially suppress or inflate Fusobacterium readings. Wait at least four to six weeks after finishing antibiotics before testing.
• Acid-suppressing medications: proton pump inhibitors (PPIs) such as omeprazole, and to a lesser extent H2 blockers like famotidine, can increase Fusobacterium in the gut within a week of starting them. This is a real biological shift, but it reflects the drug, not underlying bowel disease.
• Recent oral bleeding or dental work: because Fn is abundant in dental plaque, active gum bleeding, recent extractions, or swallowed blood can transiently raise the stool signal.
• Sample handling: anaerobic bacteria like Fusobacterium are sensitive to how stool is collected and preserved. Follow your lab's collection protocol exactly, especially around refrigeration and return shipping time.

Tracking Your Trend

One reading is a starting point. Because gut microbiome composition varies day to day and because labs differ in assay sensitivity, the direction of change matters more than any single value. If you are making gut-focused changes, such as shifting to a higher-fiber diet, treating gum disease, stepping down acid suppression, or taking antimicrobials for a known overgrowth, a retest in three to six months will tell you whether the change is working. After that, annual monitoring is reasonable for anyone using this as part of a longevity workup. If you are in an elevated tier, retest sooner and track alongside stool calprotectin (an inflammation marker) and commensal species like Faecalibacterium prausnitzii and Akkermansia muciniphila.

What to Do If Your Level Is High

An elevated Fusobacterium reading is a prompt to investigate, not a diagnosis. First, look at it alongside the rest of your stool panel. High Fusobacterium paired with elevated calprotectin, low diversity, or depleted short-chain fatty acid producers is a stronger signal than an isolated number.

Second, update your colorectal cancer screening plan. If you are over 45, or younger with family history, a persistently high stool Fusobacterium with a positive FIT is a clear reason to move on colonoscopy timing rather than wait. A gastroenterologist can help interpret the combination. Third, consider the oral-gut connection. A dental cleaning and periodontal evaluation are reasonable if you have not had one in the last year. Finally, if you have IBD or ongoing gut symptoms, bring these results to the physician managing your bowel care so they can factor Fusobacterium and dysbiosis patterns into treatment decisions.